Johnson & Johnson vs. Xenon Pharmaceuticals Inc
Johnson & Johnson (JNJ) comes out ahead, leading on 4 of 6 compared factors.
Size & Scale
| JNJ | XENE | |
|---|---|---|
| Market Cap | $628.65 billion | $6.31 billion |
| Revenue (TTM) | $97.93 billion | — |
| Net Income (TTM) | $21.04 billion | $-409,195,000 |
JNJ leads on 3 of 3 size & scale factors.
Valuation
| JNJ | XENE | |
|---|---|---|
| P/E Ratio | 30.26 | — |
| Price / Book | 7.40 | 5.08 |
| Price / Sales | 6.42 | — |
XENE leads on 1 of 1 valuation factors.
Profitability
| JNJ | XENE | |
|---|---|---|
| Net Margin | 21.48% | — |
| Return on Equity | 24.76% | -32.94% |
JNJ leads on 1 of 1 profitability factors.
Dividend
| JNJ | XENE | |
|---|---|---|
| Dividend Yield | 2.05% | — |
| Payout Ratio | 62.18 | — |
JNJ and XENE split the dividend factors evenly.
Risk & Sentiment
| JNJ | XENE | |
|---|---|---|
| Short Interest | 0.67% | 0.15% |
XENE leads on 1 of 1 risk & sentiment factors.
Dig deeper: JNJ overview, JNJ financials, XENE overview, XENE financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.